New mRNA vaccines aim to outsmart evolving COVID variants

NCT ID NCT06585241

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests several updated mRNA COVID-19 vaccines designed to target new variants of the virus. About 1,100 adults and children with certain risk factors will receive one of the vaccines to see how well it boosts immunity and how safe it is. The goal is to ensure vaccines remain effective as the virus changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease viral infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV-2

Contacts and locations

Locations

CenExel
RECRUITING

Atlanta, Georgia, 30331, United States
CenExel
RECRUITING

Decatur, Georgia, 30030, United States
Richard Bennett - Clinical Research Partners
RECRUITING

Richmond, Virginia, 23226, United States
Velocity Clinical Research
RECRUITING

Baton Rouge, Louisiana, 70809, United States
Velocity Clinical Research
RECRUITING

Gulfport, Mississippi, 39503, United States
Velocity Clinical Research
RECRUITING

Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.